Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W J Sandborn

Showing results (111-120 of 186) with videos related to

Pageof 19
Sort By:
Inflammatory Bowel Diseases|June 1, 2001
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot studyB E Sands, W J Tremaine, W J Sandborn, et al.
Alimentary Pharmacology & Therapeutics|June 2, 2007
Age at onset of inflammatory bowel disease and the risk of surgery for non-neoplastic bowel diseaseW J Tremaine, L J Timmons, E V Loftus, et al.
Inflammatory Bowel Diseases|August 29, 2000
Pouchitis is associated with mucosal imbalance between interleukin-8 and interleukin-10P Bulois, W J Tremaine, V Maunoury, et al.
Hepatology (Baltimore, Md.)|March 21, 1998
Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantationE V Loftus, H I Aguilar, W J Sandborn, et al.
Gut|December 14, 2004
PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitisE V Loftus, G C Harewood, C G Loftus, et al.
Digestive Diseases and Sciences|July 1, 1995
Fecal bile acids, short-chain fatty acids, and bacteria after ileal pouch-anal anastomosis do not differ in patients with pouchitisW J Sandborn, W J Tremaine, K P Batts, et al.
Alimentary Pharmacology & Therapeutics|March 2, 2017
Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritisP B Allen, P Olivera, P Emery, et al.
Journal of Crohn'S & Colitis|June 19, 2012
Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's diseaseS Schreiber, W Reinisch, J F Colombel, et al.
Gut|October 16, 2001
Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel diseaseP W Lowry, C L Franklin, A L Weaver, et al.
Gastroenterology|June 26, 1999
Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohortM D Silverstein, E V Loftus, W J Sandborn, et al.
Pageof 19

Showing results (111-120 of 186) with videos related to

Sort By:
Pageof 19
Inflammatory Bowel Diseases|June 1, 2001
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot studyB E Sands, W J Tremaine, W J Sandborn, et al.
Alimentary Pharmacology & Therapeutics|June 2, 2007
Age at onset of inflammatory bowel disease and the risk of surgery for non-neoplastic bowel diseaseW J Tremaine, L J Timmons, E V Loftus, et al.
Inflammatory Bowel Diseases|August 29, 2000
Pouchitis is associated with mucosal imbalance between interleukin-8 and interleukin-10P Bulois, W J Tremaine, V Maunoury, et al.
Hepatology (Baltimore, Md.)|March 21, 1998
Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantationE V Loftus, H I Aguilar, W J Sandborn, et al.
Gut|December 14, 2004
PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitisE V Loftus, G C Harewood, C G Loftus, et al.
Digestive Diseases and Sciences|July 1, 1995
Fecal bile acids, short-chain fatty acids, and bacteria after ileal pouch-anal anastomosis do not differ in patients with pouchitisW J Sandborn, W J Tremaine, K P Batts, et al.
Alimentary Pharmacology & Therapeutics|March 2, 2017
Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritisP B Allen, P Olivera, P Emery, et al.
Journal of Crohn'S & Colitis|June 19, 2012
Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's diseaseS Schreiber, W Reinisch, J F Colombel, et al.
Gut|October 16, 2001
Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel diseaseP W Lowry, C L Franklin, A L Weaver, et al.
Gastroenterology|June 26, 1999
Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohortM D Silverstein, E V Loftus, W J Sandborn, et al.
Pageof 19